Search for: [Abstract = "TE patients resulted in TC, LDL\-C reduction \(p for all < 0.0001\), no change in CRP concentration and a decrease in tHcy \(by 31.6%, p= 0.006\), PAI\-1 \(by 19.4%, p= 0.009\), Lp\(a\) \(by 7.2%, p= 0.0006\) levels. VTE patients following atorvastatin administration had an increase in Ks \(by 23.2%, p< 0.0001\), lag phase \(by 4.5%, p= 0.04\), D\-D rate \(by 10.3%, p< 0.0001\) and decrease in Δ Abs \(by 4.5%, p= 0.002\), t50% \(by 19.9%, p< 0.0001\) and CLT \(by 13.7%, p= 0.0004\). Atorvastatin\-induced reduction of Δ Abs was more pronounced in patients with RVT as compared to patients without RVT \(0.10 ±0.07 vs 0.01 ±0.07, p= 0.005\), while CLT reduction was seen only in patients without RVT. D\-D rate increase following atorvastatin was higher in unprovoked \(n=10\) than provoked VTE \(0.012 mg\/l\/min ±0.01 vs 0.005 mg\/l\/min ±0.006, p= 0.044, respectively\). Patients with proximal venous thrombosis \(n=17\), contrary to distal thrombosis patients, displayed Δ Abs reduction following atorvastatin administration \(p= 0,01\). Thrombophilia \(n=14\) did not alter fibrin clot properties either before or after statin administration. The improvement of fibrin clot structure\/function in VTE patients after atorvastatin was unrelated to TC or tHcy, t\-PA, PAI\-1, F1.2, Lp\(a\) changes. \; In conclusion, the present study confirms that fibrin clots in VTE patients are less permeable, more compact and resistant to lysis compared"]

Number of results: 1